Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 3.0 %

CHEK stock opened at $0.80 on Friday. The company’s fifty day simple moving average is $1.06 and its 200 day simple moving average is $1.20. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.45. The firm has a market cap of $4.70 million, a price-to-earnings ratio of -0.27 and a beta of 0.19.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.